Agenovir

Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt intracellular viral DNA. It raised a $10.6M Series A led by DCVC (Data Collective) with Celgene and Lightspeed Venture Partners, and was acquired by Vir Biotechnology in 2018. It is a therapeutics company with no public developer, API, or SDK surface.

Agenovir is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, CRISPR, and Gene Editing.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Biotechnology Therapeutics CRISPR Gene EditingAntiviralLife Sciences Acquired

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/agenovir: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: agenovir
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/agenovir.png
name: Agenovir
description: Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics
  targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from
  the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt intracellular viral
  DNA. It raised a $10.6M Series A led by DCVC (Data Collective) with Celgene and Lightspeed Venture Partners, and was acquired
  by Vir Biotechnology in 2018. It is a therapeutics company with no public developer, API, or SDK surface.
url: https://raw.githubusercontent.com/api-evangelist/agenovir/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Vir Biotechnology
x-acquired-year: 2018
x-api-surface: none
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Therapeutics
- CRISPR
- Gene Editing
- Antiviral
- Life Sciences
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 0
  pass: local-v1